Sermorelin
MetabolicEndocrine and metabolic applications of Sermorelin span direct incretin-axis engagement, AMPK and mitochondrial signalling, and adiposity-driven inflammation. The 29-amino-acid biologically active fragment of GHRH — once FDA-approved for pediatric GH deficiency, now widely used off-label for adult age-related GH decline. The ~10-20 min pharmacokinetic profile and subq administration shape the rate at which glycemic markers move; the typical Sermorelin effect window in metabolic syndrome populations is 8-12 weeks.
Key Takeaways
Metabolic lens: Sermorelin is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: GHRH receptor agonist on pituitary somatotrophs. Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 200-500 mcg 1x daily subq (evening) via subq. Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
GHRH receptor agonist on pituitary somatotrophs. Stimulates endogenous GH release while preserving the natural pulsatile pattern and negative feedback regulation, which lowers the risk of receptor desensitisation compared to exogenous GH. The metabolic medicine framework evaluates Sermorelin against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.
Visceral fat and the cardiometabolic axis
Sermorelin's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral fat is one of the more responsive endpoints for this class. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.
Weight management and the appetite circuit
Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.
Insulin signalling and glycemic effect
Sermorelin's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
Where Sermorelin is used for liver metabolism, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
Sermorelin for visceral fat reduction is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
In the metabolic syndrome population, Sermorelin for cardiometabolic risk produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
Where Sermorelin is used for fatty liver research, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 200-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 120-500 mcg | 4–6 weeks initial cycle |
| Metabolic focus | SubQ | 200-500 mcg | 1x daily SubQ (evening) |
| Maintenance phase | SubQ | 140-500 mcg | Ongoing with periodic pauses |
Dose timing for Sermorelin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
Sermorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- Sermorelin + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with Sermorelin's mechanism in metabolic / endocrine protocols.
- Sermorelin + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with Sermorelin's mechanism in metabolic / endocrine protocols.
- Sermorelin + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Sermorelin's mechanism in metabolic / endocrine protocols.
- Sermorelin + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with Sermorelin's mechanism in metabolic / endocrine protocols.
Site reactions occasional. Headache, flushing possible. Long pulsatile use generally safer than exogenous GH.
Lens-specific safety considerations for metabolic / endocrine use of Sermorelin: Site reactions occasional. Headache, flushing possible. Long pulsatile use generally safer than exogenous GH. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Sermorelin | Truncated GHRH analogue | ~10-20 min | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
Will Sermorelin affect my muscle mass during weight loss?
Pancreatitis or thyroid risk?
What metabolic labs should I track?
What weight loss can I expect?
What class of compound is Sermorelin?
What is the regulatory status of Sermorelin?
Start a Sermorelin Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified Sermorelin and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- 3358 Da
- Sequence length
- 29 aa
- Half-life
- ~10-20 min
- WADA
- Banned (S2)
- FDA
- Approval withdrawn 2008 (commercial reasons); compounded prescription use widespread
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Sermorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for Sermorelin
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised